{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:51:58Z","timestamp":1788997918815,"version":"build-2803163510"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"Importance<\/jats:title>Psoriasis is an inflammatory condition associated with metabolic and cardiovascular disease. Apremilast, a phosphodiesterase 4 inhibitor, is commonly used for psoriasis and can cause weight loss.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine the association between apremilast and aortic vascular inflammation as assessed by 18<\/jats:sup>F-fluorodeoxyglucose positron emission tomography\/computed tomography (FDG-PET\/CT), cardiometabolic markers (primary outcomes at week 16), and abdominal fat composition.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A single-arm, open-label, interventional, nonrandomized clinical trial in which the imaging and laboratory outcomes were measured by an investigator who was blinded to time was conducted between April 11, 2017, and August 17, 2021, at 7 dermatology sites in the United States. A total of 101 patients with moderate to severe psoriasis were screened, 70 enrolled, 60 completed week 16, and 39 completed week 52.<\/jats:p><\/jats:sec>Intervention<\/jats:title>Apremilast, 30 mg, twice daily.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Aortic vascular inflammation (measured by FDG-PET\/CT), 68 cardiometabolic biomarkers, and abdominal fat composition (measured by CT) at week 16 and week 52 compared with baseline.<\/jats:p><\/jats:sec>Results<\/jats:title>The mean (SD) age of the 70 patients was 47.5 (14.6) years, 54 were male (77.1%), 4 were Black (5.7%), and 58 were White (82.9%). There was no change in aortic vascular inflammation at week 16 (target to background ratio, \u22120.02; 95% CI, \u22120.08 to 0.05; P<\/jats:italic>\u2009=\u2009.61) or week 52 (target to background ratio, \u22120.07; 95% CI, \u22120.15 to 0.01; P<\/jats:italic>\u2009=\u2009.09) compared with baseline. At week 16, potentially beneficial decreases in interleukin 1b, valine, leucine, isoleucine, fetuin A, and branched-chain amino acids were observed. At week 52 compared with baseline, potentially beneficial decreases in ferritin, \u03b2-hydroxybutyrate, acetone, and ketone bodies, with an increase in apolipoprotein A-1, were observed, but there was a reduction in cholesterol efflux. There was an approximately 5% to 6% reduction in subcutaneous and visceral adiposity at week 16 that was maintained at week 52.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>The findings of this nonrandomized clinical trial suggest that apremilast has a neutral association with aortic vascular inflammation, variable but generally beneficial associations with a subset of cardiometabolic biomarkers, and associations with reductions in visceral and subcutaneous fat, indicating that the drug may have an overall benefit for patients with cardiometabolic disease and psoriasis.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT03082729<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2022.3862","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T15:06:42Z","timestamp":1663772802000},"page":"1394","source":"Crossref","is-referenced-by-count":44,"title":["Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis"],"prefix":"10.1001","volume":"158","author":[{"given":"Joel M.","family":"Gelfand","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Tyring","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Texas Health Science Center at Houston, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Oregon Medical Research Center, Portland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Gottlieb","sequence":"additional","affiliation":[{"name":"Dermatology and Skin Surgery Center, Exton, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Lockshin","sequence":"additional","affiliation":[{"name":"DermAssociates, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Kalb","sequence":"additional","affiliation":[{"name":"SUNY at Buffalo School of Medicine and Biomedical Sciences, Department of Dermatology, Buffalo Medical Group, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Fitzsimmons","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Rodante","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Parel","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grigory A.","family":"Manyak","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan H.","family":"Noe","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryte","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha N.","family":"Syed","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Werner","sequence":"additional","affiliation":[{"name":"Department of Radiology (Nuclear Medicine), Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Playford","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abass","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Radiology (Nuclear Medicine), Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[{"name":"Section of Inflammation and Cardiometabolic Diseases, National Heart, Lung, and Blood Institute, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"doi220050r1","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2133.2010.09941.x","article-title":"Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the United Kingdom.","volume":"163","author":"Abuabara","year":"2010","journal-title":"Br J Dermatol"},{"issue":"3","key":"doi220050r2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: epidemiology.","volume":"76","author":"Takeshita","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"24","key":"doi220050r3","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"doi220050r4","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi220050r5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaad.2017.10.050","article-title":"Psoriasis and the risk of diabetes: a prospective population-based cohort study.","volume":"78","author":"Wan","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"doi220050r6","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1161\/ATVBAHA.115.306460","article-title":"Severity of psoriasis associates with aortic vascular inflammation detected by FDG PET\/CT and neutrophil activation in a prospective observational study.","volume":"35","author":"Naik","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3, pt 1","key":"doi220050r7","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/jid.2011.365","article-title":"Prevalence of metabolic syndrome in patients with psoriasis: a population-based study in the United Kingdom.","volume":"132","author":"Langan","year":"2012","journal-title":"J Invest Dermatol"},{"issue":"12","key":"doi220050r8","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis.","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"doi220050r9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1177\/1759720X10381432","article-title":"Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases.","volume":"2","author":"Schett","year":"2010","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"doi220050r10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/eht398","article-title":"Targeting inflammatory pathways for the treatment of cardiovascular disease.","volume":"35","author":"Ridker","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"doi220050r11","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1165\/rcmb.2008-0091TR","article-title":"Cyclic AMP: master regulator of innate immune cell function.","volume":"39","author":"Serezani","year":"2008","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"doi220050r12","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40259-015-0144-3","article-title":"Selective phosphodiesterase inhibitors for psoriasis: focus on apremilast.","volume":"29","author":"Gooderham","year":"2015","journal-title":"BioDrugs"},{"issue":"6","key":"doi220050r13","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.117.007394","article-title":"Effect of 2 psoriasis treatments on vascular inflammation and novel inflammatory cardiovascular biomarkers: a randomized placebo-controlled trial.","volume":"11","author":"Mehta","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"doi220050r14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jid.2019.07.679","article-title":"A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial).","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"9","key":"doi220050r15","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jid.2020.01.025","article-title":"A randomized placebo-controlled trial of secukinumab on aortic vascular inflammation in moderate-to-severe plaque psoriasis (VIP-S).","volume":"140","author":"Gelfand","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"1","key":"doi220050r16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s00259-008-0947-2","article-title":"Emerging role of FDG-PET\/CT in assessing atherosclerosis in large arteries.","volume":"36","author":"Chen","year":"2009","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"doi220050r17","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1007\/s00259-007-0528-9","article-title":"FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries.","volume":"35","author":"Bural","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"doi220050r18","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.nucmedbio.2006.08.005","article-title":"Quantitative assessment of the atherosclerotic burden of the aorta by combined FDG-PET and CT image analysis: a new concept.","volume":"33","author":"Bural","year":"2006","journal-title":"Nucl Med Biol"},{"issue":"9","key":"doi220050r19","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1001\/archdermatol.2011.119","article-title":"Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET\/CT): a pilot study.","volume":"147","author":"Mehta","year":"2011","journal-title":"Arch Dermatol"},{"issue":"39","key":"doi220050r20","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1093\/eurheartj\/ehv339","article-title":"Cholesterol efflux capacity in humans with psoriasis is inversely related to non-calcified burden of coronary atherosclerosis.","volume":"36","author":"Salahuddin","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"doi220050r21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2214\/AJR.11.7842","article-title":"Association between visceral adiposity and colorectal polyps on CT colonography.","volume":"199","author":"Summers","year":"2012","journal-title":"AJR Am J Roentgenol"},{"issue":"22","key":"doi220050r22","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.142534","article-title":"Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time.","volume":"5","author":"Sajja","year":"2020","journal-title":"JCI Insight"},{"issue":"2, pt 2","key":"doi220050r23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jcmg.2017.08.014","article-title":"Visceral adiposity in psoriasis is associated with vascular inflammation by 18F-fluorodeoxyglucose positron-emission tomography\/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study.","volume":"11","author":"Rivers","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12","key":"doi220050r24","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease.","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"doi220050r25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1039\/C3MT00347G","article-title":"Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells.","volume":"6","author":"Kell","year":"2014","journal-title":"Metallomics"},{"issue":"4","key":"doi220050r26","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCGEN.118.002157","article-title":"Circulating branched-chain amino acids and incident cardiovascular disease in a prospective cohort of US women.","volume":"11","author":"Tobias","year":"2018","journal-title":"Circ Genom Precis Med"},{"issue":"22","key":"doi220050r27","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1161\/CIRCULATIONAHA.119.045033","article-title":"Implications of altered ketone metabolism and therapeutic ketosis in heart failure.","volume":"141","author":"Selvaraj","year":"2020","journal-title":"Circulation"},{"issue":"3","key":"doi220050r28","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1161\/ATVBAHA.117.307025","article-title":"From high-density lipoprotein cholesterol to measurements of function: prospects for the development of tests for high-density lipoprotein functionality in cardiovascular disease.","volume":"38","author":"Sacks","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"doi220050r29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","article-title":"Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).","volume":"73","author":"Papp","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi220050r30","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/j.jid.2017.02.977","article-title":"TNF-a antagonist and vascular inflammation in patients with psoriasis vulgaris: a randomized placebo-controlled study.","volume":"137","author":"Bissonnette","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi220050r31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/jdv.v36.2","article-title":"Apremilast effectively inhibits TNFa-induced vascular inflammation in human endothelial cells.","volume":"36","author":"Otto","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi220050r32","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease\u2014results of the Immune Metabolic Associations in Psoriatic Arthritis study.","volume":"61","author":"Ferguson","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"doi220050r33","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1111\/joim.v291.5","article-title":"The clinical and molecular cardiometabolic fingerprint of an exploratory psoriatic arthritis cohort is associated with the disease activity and differentially modulated by methotrexate and apremilast.","volume":"291","author":"Arias de la Rosa","year":"2022","journal-title":"J Intern Med"},{"issue":"4","key":"doi220050r34","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids.","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"doi220050r35","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study.","volume":"61","author":"Pina Vegas","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"doi220050r36","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/j.jid.2021.03.024","article-title":"Impact of biological agents on imaging and biomarkers of cardiovascular disease in patients with psoriasis: a systematic review and meta-analysis of randomized placebo-controlled trials.","volume":"141","author":"Gonz\u00e1lez-Cantero","year":"2021","journal-title":"J Invest Dermatol"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2796165\/jamadermatology_gelfand_2022_oi_220050_1670609101.4998.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T16:12:01Z","timestamp":1671639121000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2796165"}},"subtitle":["The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,12,1]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2022.3862","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,1]]}}}